BioWorld - Friday, December 26, 2025
To read the full story, subscribe or sign in.
Cancer
Shenzhen Forward Pharmaceuticals discovers new FGFR2 inhibitors
Dec. 3, 2025
Shenzhen Forward Pharmaceuticals Co. Ltd. has described fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of stomach cancer and intrahepatic cholangiocarcinoma.
BioWorld ScienceCancerPatents